

# COVID-19 Pfizer (Comirnaty) vaccine information

## 5 - 11 YEAR OLDS

Please read this information sheet carefully and ensure all your questions have been answered by a health-care provider before your child receives their vaccine. This information sheet is specifically for the Pfizer pediatric vaccine for children age 5 to 11. There is another information sheet for those age 12 and older.

### What vaccine will my 5 to 11 year old child receive?

Your child will receive the Pfizer (Comirnaty) pediatric COVID-19 vaccine.

- Children age 5 to 11 receive 10 micrograms per dose.
- Youth age 12 and older receive 30 micrograms per dose.
- If your child turns 12 in between doses, they will receive 30 micrograms for their following dose.

### How is the vaccines given?

Your child will need 2 (sometimes 3\*\*) doses of Pfizer (Comirnaty) vaccine to get full protection. This is called the primary series.

Your child will receive the vaccine via a needle in their upper arm (deltoid muscle). The vaccine doses are recommended to be given 8 weeks apart. Evidence shows an 8 week interval between first and second doses results in:

- stronger immune response
- higher vaccine effectiveness that is expected to last longer
- fewer side effects
- Booster doses are given 6 months after completion of the primary series.

### How does the Pfizer mRNA vaccine work?

- mRNA vaccines teach your body to protect itself against COVID-19 without getting sick from the virus.
- The vaccine causes your body to produce antibodies to help keep you from becoming sick if you are exposed to the COVID-19 virus.

### What are the benefits of the vaccine?

- Vaccines are the best protection against COVID-19 infection. In clinical trials, the vaccine prevented children age 5 to 11 from becoming sick with COVID-19 and from severe illness (hospitalization and death) with 90.7% efficacy.

### Who can get the COVID-19 vaccine?

COVID-19 vaccines have now been approved for those age 5 and older. In the Yukon the following COVID-19 vaccines are available:

- Children between 6 months and 4 years old receive the Moderna (Spikevax) vaccine, in a 25 microgram dose.
- Children between age 5 to 11 receive the Pfizer (Comirnaty) pediatric vaccine, in a 10 microgram dose.
- Youth and adults aged 12-29 receive Pfizer (comirnaty) vaccine, a 30 microgram dose.
- Adults aged 30 and older receive the Moderna (Spikevax) vaccine, in a 100 microgram dose.

### Who should not receive a COVID-19 vaccine?

- Anyone under 6 months of age. There are currently no COVID-19 vaccines approved for infants this age range.
- Anyone with symptoms that could be due to COVID-19 should wait to be vaccinated so that they do not spread infection to others at the vaccine clinic. Talk with a health-care provider, call 811, or arrange to get tested for COVID-19.
- Anyone with a known allergy to polyethylene glycol (PEG)\* or who has had an allergic reaction from an unknown cause should speak with their health care provider.
- People who had a serious or allergic reaction to a previous dose of COVID-19 vaccine should talk to their health-care provider before getting their next dose.

\* Polyethylene glycol (PEG) can rarely cause allergic reactions. It is found in products such as medications, bowel preparation products for colonoscopy, laxatives, cough syrups, cosmetics, skin creams, medical products used on the skin and during operations, toothpaste, contact lenses and contact lens solution. PEG also can be found in foods or drinks, but is not known to cause allergic reactions from foods or drinks.

\*\*A third dose of vaccine is recommended for some people who have a weakened immune system, as they may not develop a strong immune response to the vaccine.

**Note:** Rare cases of inflammation of the heart (myocarditis and pericarditis) have been reported after getting the COVID-19 mRNA vaccines. In Canada, this has occurred at a rate of about 3 cases per 100,000 doses of Moderna (Spikevax) vaccine and 1.9 cases per 100,000 doses of Pfizer-BioNTech (Comirnaty) vaccine. Cases are seen more often after the second dose and in males 12-29 years of age. The rate of cases in males 18-29 years of age after the second dose are about 6 times higher with the Moderna (Spikevax) vaccine compared to the Pfizer-BioNTech (Comirnaty) vaccine.

This is why Pfizer is being recommended as the vaccine of choice for those under 30 years of age.

This very rare reaction was not observed during the Pfizer (Comirnaty) clinical trials for those age 5 to 11.

For more information visit [www.yukon.ca/en/heart-inflammation-and-covid-19-mrna-vaccines](http://www.yukon.ca/en/heart-inflammation-and-covid-19-mrna-vaccines).